Multivariate analysis of chronic GVHD with systemic steroid therapy in the UCB cohort
| Risk factors . | Adjustment for acute GVHD . | |||
|---|---|---|---|---|
| No . | Yes . | |||
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Acute GVHD | ||||
| None | NA | NA | Reference | 1.0 |
| Grade 1 | NA | NA | 1.38 (1.08-1.76) | .0092 |
| Grade 2 | NA | NA | 2.38 (1.97-2.88) | <.001 |
| Grade 3-4 | NA | NA | 2.71 (2.14-3.41) | <.001 |
| Age | ||||
| ≤56 y | 1.09 (0.91-1.29) | .35 | 1.06 (0.90-1.27) | .48 |
| 36-55 y | Reference | 1.0 | Reference | 1.0 |
| 16-35 y | 0.89 (0.71-1.12) | .32 | 0.88 (0.70-1.11) | .29 |
| Sex mismatch | ||||
| Match or male-to-female | Reference | 1.0 | Reference | 1.0 |
| Female-to-male | 1.08 (0.92-1.27) | .36 | 1.12 (0.95-1.31) | .17 |
| Disease risk index | ||||
| Low | Reference | 1.0 | Reference | 1.0 |
| Intermediate | 0.88 (0.64-1.19) | .40 | 0.91 (0.67-1.24) | .56 |
| High | 0.81 (0.59-1.11) | .19 | 0.81 (0.59-1.11) | .19 |
| Very high | 0.91 (0.62-1.33) | .62 | 0.93 (0.63-1.36) | .70 |
| HCT-CI | ||||
| 0-1 | Reference | 1.0 | Reference | 1.0 |
| ≥2 | 1.00 (0.85-1.19) | .97 | 0.98 (0.82-1.16) | .78 |
| Conditioning regimen | ||||
| MAC | Reference | 1.0 | Reference | 1.0 |
| RIC | 0.76 (0.65-0.90) | .0018 | 0.81 (0.69-0.96) | .016 |
| GVHD prophylaxis | ||||
| CsA based | Reference | 1.0 | Reference | 1.0 |
| TAC based | 1.21 (0.99-1.48) | .065 | 1.25 (1.02-1.53) | .029 |
| In vivo T-cell depletion | ||||
| No | Reference | 1.0 | Reference | 1.0 |
| Yes | 0.74 (0.47-1.18) | .21 | 0.74 (0.47-1.18) | .20 |
| Risk factors . | Adjustment for acute GVHD . | |||
|---|---|---|---|---|
| No . | Yes . | |||
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Acute GVHD | ||||
| None | NA | NA | Reference | 1.0 |
| Grade 1 | NA | NA | 1.38 (1.08-1.76) | .0092 |
| Grade 2 | NA | NA | 2.38 (1.97-2.88) | <.001 |
| Grade 3-4 | NA | NA | 2.71 (2.14-3.41) | <.001 |
| Age | ||||
| ≤56 y | 1.09 (0.91-1.29) | .35 | 1.06 (0.90-1.27) | .48 |
| 36-55 y | Reference | 1.0 | Reference | 1.0 |
| 16-35 y | 0.89 (0.71-1.12) | .32 | 0.88 (0.70-1.11) | .29 |
| Sex mismatch | ||||
| Match or male-to-female | Reference | 1.0 | Reference | 1.0 |
| Female-to-male | 1.08 (0.92-1.27) | .36 | 1.12 (0.95-1.31) | .17 |
| Disease risk index | ||||
| Low | Reference | 1.0 | Reference | 1.0 |
| Intermediate | 0.88 (0.64-1.19) | .40 | 0.91 (0.67-1.24) | .56 |
| High | 0.81 (0.59-1.11) | .19 | 0.81 (0.59-1.11) | .19 |
| Very high | 0.91 (0.62-1.33) | .62 | 0.93 (0.63-1.36) | .70 |
| HCT-CI | ||||
| 0-1 | Reference | 1.0 | Reference | 1.0 |
| ≥2 | 1.00 (0.85-1.19) | .97 | 0.98 (0.82-1.16) | .78 |
| Conditioning regimen | ||||
| MAC | Reference | 1.0 | Reference | 1.0 |
| RIC | 0.76 (0.65-0.90) | .0018 | 0.81 (0.69-0.96) | .016 |
| GVHD prophylaxis | ||||
| CsA based | Reference | 1.0 | Reference | 1.0 |
| TAC based | 1.21 (0.99-1.48) | .065 | 1.25 (1.02-1.53) | .029 |
| In vivo T-cell depletion | ||||
| No | Reference | 1.0 | Reference | 1.0 |
| Yes | 0.74 (0.47-1.18) | .21 | 0.74 (0.47-1.18) | .20 |
Abbreviations are explained in Table 1.